FindTrial
Sign In

Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Pre-viously Untreated Extensive-Stage Small-Cell Lung Cancer: A Systematic Review and Network Me-ta-analysis

Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Pre-viously Untreated Extensive-Stage Small-Cell Lung Cancer: A Systematic Review and Network Me-ta-analysis - Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Pre-viously Untreated Extensive-Stage Small-Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041702
Enrollment
2000
Registered
2020-09-07
Start date
2020-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive stage small cell lung cancer

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with cytologically or histologically confirmed advanced small cell lung cancer. Performance status 0 to 2 Not received previous systemic anti-cancer treatment.

Exclusion criteria

Exclusion criteria: non-small cell lung cancer patients Poor performance status (3 or more) Patients previously treated with systemic anticancer therapy

Design outcomes

Primary

MeasureTime frame
overall survival—

Secondary

MeasureTime frame
progression free survival Incidence of Grade 3 or higher any adverse events Incidence of Grade 3 or higher neutropenia, anemia, and thrombocytopenia—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp+81-3-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026